SYNDESI THERAPEUTICS: what changed
SYNDESI THERAPEUTICS
Largest movements
- Receivables within one year -€811,290
down €811,290 (-89.7%), from €904,241 to €92,951
of which Trade receivables: -€812,667
- Receivables after one year -€214,451
down €214,451 (-29.4%), from €729,032 to €514,581
- Accrued charges and deferred income +€14.1m
new in 2025: €14.1m
- Profit (loss) carried forward -€12.0m
down €12.0m (-8.1%), from -€147.3m to -€159.2m
- Other debts -€3.2m
down €3.2m (-2.7%), from €119.5m to €116.2m
- Trade debts +€36,237
up €36,237 (+29.9%), from €121,386 to €157,623
- Gross operating margin +€43.0m
up €43.0m (+86.9%), from -€49.5m to -€6.5m
- Financial charges -€5.5m
down €5.5m (-49.7%), from €11.1m to €5.6m
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
Cash or the result is not a separate line in both sets of accounts. So the cash flow cannot be derived from them.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,633,274 | €607,532 | -€1.0m | -62.8% |
| Fixed assets | 21/28 | €0 | €0 | = | |
| Intangible fixed assets | 21 | €0 | €0 | = | |
| Current assets | 29/58 | €1,633,274 | €607,532 | -€1.0m | -62.8% |
| Amounts receivable after more than one year | 29 | €729,032 | €514,581 | -€214,451 | -29.4% |
| Other amounts receivable | 291 | €729,032 | €514,581 | -€214,451 | -29.4% |
| Amounts receivable within one year | 40/41 | €904,241 | €92,951 | -€811,290 | -89.7% |
| Trade receivables | 40 | €904,241 | €91,574 | -€812,667 | -89.9% |
| Other amounts receivable | 41 | - | €1,377 | +€1,377 | |
| Total equity and liabilities | 10/49 | €1,633,274 | €607,532 | -€1.0m | -62.8% |
| Equity | 10/15 | -€117,964,848 | -€129,921,795 | -€12.0m | -10.1% |
| Contributions | 10/11 | €29,296,275 | €29,296,275 | = | 0.0% |
| Capital | 10 | €29,296,275 | €29,296,275 | = | 0.0% |
| Issued capital | 100 | €29,296,275 | €29,296,275 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€147,261,123 | -€159,218,070 | -€12.0m | -8.1% |
| Amounts payable | 17/49 | €119,598,122 | €130,529,327 | +€10.9m | +9.1% |
| Amounts payable within one year | 42/48 | €119,598,122 | €116,392,665 | -€3.2m | -2.7% |
| Trade debts | 44 | €121,386 | €157,623 | +€36,237 | +29.9% |
| Suppliers | 440/4 | €121,386 | €157,623 | +€36,237 | +29.9% |
| Other amounts payable | 47/48 | €119,476,736 | €116,235,042 | -€3.2m | -2.7% |
| Accrued charges and deferred income | 492/3 | - | €14,136,662 | +€14.1m | |
| Gross operating margin | 9900 | -€49,488,494 | -€6,461,490 | +€43.0m | +86.9% |
| Operating profit (loss) | 9901 | -€49,488,494 | -€6,461,490 | +€43.0m | +86.9% |
| Financial income | 75/76B | €1,531 | €80,311 | +€78,779 | +5,144% |
| Recurring financial income | 75 | €1,531 | €80,311 | +€78,779 | +5,144% |
| Financial charges | 65/66B | €11,077,110 | €5,575,769 | -€5.5m | -49.7% |
| Recurring financial charges | 65 | €11,077,110 | €5,575,769 | -€5.5m | -49.7% |
| Profit (loss) for the period before taxes | 9903 | -€60,564,073 | -€11,956,947 | +€48.6m | +80.3% |
| Profit (loss) for the period | 9904 | -€60,564,073 | -€11,956,947 | +€48.6m | +80.3% |
| Profit (loss) for the period to be appropriated | 9905 | -€60,564,073 | -€11,956,947 | +€48.6m | +80.3% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 6 November 2026 via checked.be.